Vascular endothelial growth factor (VEGF) inhibitors, while mechanistically relevant, showed contraindications due to the tumor's proximity to major blood vessels and a history of gastric ulcers, posing a high risk of hemorrhage. The gene discussed is VEGFA; the disease is gastric ulcer.